Program
Erythromycin
Also written as “erythromycin”, “Erythromycin (normal renal function)” and “Erythromycin (mild and moderate renal function)”.
Its studies are mostly in Obesity · Pulmonary Disease, Chronic Obstructive · Renal Insufficiency · Blepharitis · Hepatitis C, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 20 open or running | phase 1since Feb 17, 2011 | Feb 17, 2011 | none ahead |
| Ectycell SASU | 10 open or running | phase 1since Apr 15, 2011 | Apr 15, 2011 | none ahead |
Also a collaborator on its studies: Bayer and Bausch Health Companies.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 17, 2011First study: phase 1 study in Renal InsufficiencyNew to Johnson & JohnsonJohnson & Johnson · NCT01309438 · 29 enrolled · United States
- Mar 10, 2011Phase 1 study in Hepatitis CJohnson & Johnson · NCT01323257 · 49 enrolled · Belgium
- Apr 15, 2011Ectycell SASU's first study: phase 1 study in Cardiology: RR / QTNew to Ectycell SASUEctycell SASU · NCT01338441 · 130 enrolled · France
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial 70S ribosome inhibitor; Bacterial 70S ribosome inhibitor; Bacterial 70S ribosome inhibitor; Bacterial 70S ribosome inhibitor”ChEMBL 37, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT01338441Cardiology: RR / QT · France | 1 | Completed | Ectycell SASU | May 2011 | 130 |
| NCT01323257Hepatitis C · Belgium | 1 | Completed | Johnson & Johnson | 49 | |
| NCT01309438Renal Insufficiency · United States | 1 | Completed | Johnson & Johnson | Mar 2012 | 29 |
How it is read
Names in the registry
- “Erythromycin”, 5 entries
- “erythromycin”, 2 entries
- “Erythromycin (normal renal function)”, 1 entry
- “Erythromycin (mild and moderate renal function)”, 1 entry
- “cefuroxime plus erythromycin”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
- Renal Insufficiency, 1 study
- Blepharitis, 1 study
- Hepatitis C, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.